Objective: To evaluate whether iatrogenic hemorrhage can be prevented by intrahepatic tract ablation following radiofrequency ablation (RFA) therapy for hepatic malignancies. Methods: A retrospective cohort study analyzing a prospective database in a single institution was conducted. The incidence of postprocedural complications was compared in two groups: one with cauterization of the needle tracts after RFA and the other without. Results: The complication rates of intraperitoneal hemorrhage were 1.05% (4/380) and 0.92% (6/652) in the nonablation group and the ablation group, respectively (p = 0.90). All of these 10 patients with iatrogenic bleeding were classified as Child-Pugh grade A. Among the 15 hemodialysis patients in this study, hemorrhage was seen in 2 (13.3%), compared with 8 (0.79%) of the nonhemodialysis patients (p = 0.0002). There were no statistically significant differences in the incidence of other complications including pleural effusion, serous ascites, pneumothorax, hemothorax, hepatic infarction, bile duct injury and pericardial effusion between the two groups. Gastrointestinal perforation, peritonitis or tumor seeding were not observed. Conclusion: Our study found a high incidence of bleeding after RFA among hemodialysis patients. Irrespective of tract ablation being after RFA, iatrogenic hemorrhage appeared to be equivalent in this population.

Rossi S, Di Stasi M, Buscarini E, Cavanna L, Quaretti P, Squassante E, Garbagnati F, Buscarini L: Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1995;1:73-81.
Kudo M: Local ablation therapy for hepatocellular carcinoma: current status and future perspective. J Gastroenterol 2004;39:205-214.
Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M: A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122-130.
Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(suppl 1):S20-S37.
Lencioni R, Crocetti L: Local-regional treatment of hepatocellular carcinoma. Radiology 2012;262:43-58.
Mahnken AH, Pereira PL, de Baère T: Interventional oncologic approaches to liver metastases. Radiology 2013;266:407-430.
Minami Y, Kudo M: Radiofrequency ablation of liver metastases from colorectal cancer: a literature review. Gut Liver 2013;7:1-6.
Lin S, Hoffmann K, Schemmer P: Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-158.
Lin SM: Local ablation for hepatocellular carcinoma in Taiwan. Liver Cancer 2013;2:73-83.
Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M: Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1,000 cases. Cancer 2005;103:1201-1209.
Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S: Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008;47:82-89.
Sato M, Tateishi R, Yasunaga H, Horiguchi H, Yoshida H, Matsuda S, Koike K: Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. J Gastroenterol 2012;47:1125-1133.
Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y: Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013;58:724-729.
Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN: Treatment of focal liver tumors with percutaneous radio-frequency ablation: complication encountered in a multicenter study. Radiology 2003;226:441-451.
Rhim H, Dodd GD 3rd, Chintapalli KN, Wood BJ, Dupuy DE, Hvizda JL, Sewell PE, Goldberg SN: Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. Radiographics 2004;24:41-52.
Chen MH, Yang W, Yan K, Gao W, Dai Y, Wang YB, Zhang XP, Yin SS: Treatment efficacy of radiofrequency ablation of 338 patients with hepatic malignant tumor and the relevant complications. World J Gastroenterol 2005;11:6395-6401.
Carrafiello G, Laganà D, Ianniello A, Craparo G, Recaldini C, Lumia D, Dionigi G, Cuffari S, Fugazzola C: Bleeding after percutaneous radiofrequency ablation: successful treatment with transcatheter embolization. Eur J Radiol 2007;61:351-355.
Kasugai H, Osaki Y, Oka H, Kudo M, Seki T, Osaka Liver Cancer Study Group: Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Oncology 2007;721:72-75.
Poggi G, Riccardi A, Quaretti P, Teragni C, Delmonte A, Amatu A, Saini G, Mazzucco M, Bernardo A, Palumbo R, Canto A, Bernieri S, Bernardo G: Complications of percutaneous radiofrequency thermal ablation of primary and secondary lesions of the liver. Anticancer Res 2007;27:2911-2916.
Takaki H, Yamakado K, Nakatsuka A, Yamada T, Shiraki K, Takei Y, Takeda K: Frequency of and risk factors for complications after liver radiofrequency ablation under CT fluoroscopic guidance in 1,500 sessions: single-center experience. AJR Am J Roentgenol 2013;200:658-664.
Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, Joko K, Sato S, Tamaki K, Yamasaki T, Shibata H, Shimoe T, Matsuda T, Toshikuni N, Fujioka S, Ohmoto K, Nakamura S, Kariyama K, Aikata H, Kobayashi Y, Tsutsui A: Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: an analysis of 16,346 treated nodules in 13,283 patients. Hepatol Res 2012;42:1058-1064.
Laeseke PF, Winter TC 3rd, Davis CL, Stevens KR, Johnson CD, Fronczak FJ, Webster JG, Lee FT Jr: Postbiopsy bleeding in a porcine model: reduction with radio-frequency ablation - preliminary results. Radiology 2003;227:493-499.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.